Related Experiment Video
Updated: Aug 15, 2026

A Rat Carotid Artery Pressure-Controlled Segmental Balloon Injury with Periadventitial Therapeutic Application
Published on: July 9, 2020
Safety and Clinical Performance of Peripherics™ Paclitaxel-Coated Balloon Catheter in Below-the-Knee Arteries: A
Prashant Sarda1, PremChand Gupta2, Pradeep Burli2
1Vascular Surgery, Shri Mahant Indiresh Hospital, Dehradun, IND.
Insights
The Peripherics™ paclitaxel-coated balloon (PCB) catheter shows promising safety and effectiveness for treating below-the-knee arterial disease. This study found low complication rates and significant clinical improvement in patients within 30 days.
Area of Science:
- Vascular Surgery
- Interventional Cardiology
- Medical Device Technology
Background:
- Below-the-knee (BTK) arterial disease poses a significant risk of limb loss.
- Evidence for routine use of paclitaxel-coated balloons (PCBs) in BTK disease is limited.
- The Peripherics™ PCB catheter is a novel device for treating BTK lesions.
Purpose of the Study:
- To evaluate the safety and clinical performance of the Peripherics™ PCB catheter.
- To assess the device in routine clinical practice for BTK arterial disease.
- To determine the rate of major adverse limb events (MALE) and perioperative death (POD) at 30 days.
Main Methods:
- Retrospective, observational, multicenter, single-arm, post-market study.
- Included 70 patients with Rutherford categories III-V BTK arterial disease.
- Primary safety endpoint: 30-day MALE and POD.
Main Results:
- 71 Peripherics™ PCB catheters used in 70 patients; high technical and procedural success rates (100% and 97.1%).
- Mean ankle-brachial index improved significantly post-procedure.
- Low 30-day MALE and POD rate of 2.9% (1.4% reintervention, 1.4% death).
- 87% of patients showed clinical improvement (Rutherford class).
Conclusions:
- The Peripherics™ PCB catheter demonstrated favorable safety and clinical outcomes.
- Low event rates and significant clinical improvement were observed at 30 days.
- Supports the use of Peripherics™ PCB for BTK arterial disease treatment.
Introduction:
Below-the-knee (BTK) arterial disease is associated with a high risk of limb loss, yet evidence supporting the use of paclitaxel-coated balloons (PCB) in routine clinical practice remains limited.
Aim:
This study aimed to evaluate the safety and clinical performance of Peripherics™ PCB catheter (Sahajanand Medical Technologies Limited, Surat, India) in the treatment of BTK arteries during routine clinical practice.
Methods:
This retrospective, observational, multicenter, single-arm, investigator-initiated, post-market study was conducted between September 2022 and September 2024 at four centers in India. All consecutive patients aged ≥18 years with Rutherford categories III-V, having de novo or non-stented restenotic lesions in one or two native arteries (below the tibial plateau and above the tibiotalar joint), and treated with at least one Peripherics™ PCB catheter were included. The primary safety endpoint was 30-day major adverse limb events (MALE) and perioperative all-cause death (POD). MALE comprised above-ankle amputation or major reintervention involving a BTK artery.
Results:
A total of 71 Peripherics™ PCB catheters were used in 70 patients (mean age: 63.3±11.9 years; n=58; 82.9% male) to treat 70 lesions in BTK arteries. Rutherford class V was observed in the majority of patients (n=44; 62.9%). Thrombus was present in 39 (55.7%) lesions, total occlusion in 25 (35.7%), and calcification in 28 (40%) lesions. Device success, technical success, and procedural success were 100% (n=71), 100% (n=70), and 97.1% (n=68), respectively. The mean ankle-brachial index improved from 0.51±0.15 at baseline to 0.79±0.16 at 30 days. At 30 days, the MALE with POD was observed in two (2.9%) patients, including one patient who required thrombolysis followed by major reintervention (1.4%) and one perioperative death (1.4%). Clinical improvement was evident in 60 (87%) patients who demonstrated improvement in at least one Rutherford class.
Conclusion:
The Peripherics™ PCB catheter demonstrated favorable safety and clinical performance in the treatment of BTK arteries, with low event rates and marked clinical improvement at 30 days.
Related Concept Videos
Peripheral Artery Disease III: Interprofessional Care
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation
Peripheral Artery Disease V: Postoperative Nursing Management
